Kestra Medical Technologies (NASDAQ:KMTS) Cut to Sell at Wall Street Zen

Wall Street Zen downgraded shares of Kestra Medical Technologies (NASDAQ:KMTS) from a hold rating to a sell rating in a research report released on Sunday,Wall Street Zen reports.

Several other brokerages also recently weighed in on KMTS. Royal Bank Of Canada set a $30.00 price objective on shares of Kestra Medical Technologies in a research report on Tuesday, September 15th. Piper Sandler reissued an “overweight” rating on shares of Kestra Medical Technologies in a research note on Tuesday, September 15th. Oppenheimer initiated coverage on shares of Kestra Medical Technologies in a research report on Tuesday, July 21st. They issued a “market perform” rating for the company. Evercore started coverage on shares of Kestra Medical Technologies in a research note on Tuesday, October 20th. They issued an “outperform” rating and a $34.00 price target on the stock. Finally, Weiss Ratings raised Kestra Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, September 16th. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $29.00.

Kestra Medical Technologies Price Performance

Shares of NASDAQ KMTS opened at $29.55 on Friday. Kestra Medical Technologies has a 1-year low of $17.34 and a 1-year high of $31.91. The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.33. The business’s fifty day moving average price is $27.13 and its two-hundred day moving average price is $24.05.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its quarterly earnings results on Monday, September 14th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.14). The firm had revenue of $30.97 million for the quarter. Kestra Medical Technologies had a negative net margin of 140.43% and a negative return on equity of 63.83%. On average, analysts anticipate that Kestra Medical Technologies will post -2.45 EPS for the current fiscal year.

Insider Buying and Selling at Kestra Medical Technologies

In other Kestra Medical Technologies news, CFO Vaseem Mahboob sold 39,903 shares of the company’s stock in a transaction that occurred on Wednesday, October 28th. The stock was sold at an average price of $30.48, for a total value of $1,216,243.44. Following the completion of the sale, the chief financial officer directly owned 60,609 shares in the company, valued at $1,847,362.32. This represents a 39.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Traci S. Umberger sold 100,000 shares of the stock in a transaction on Wednesday, October 21st. The shares were sold at an average price of $27.18, for a total value of $2,718,000.00. Following the transaction, the insider directly owned 195,825 shares of the company’s stock, valued at approximately $5,322,523.50. The trade was a 33.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 266,456 shares of company stock valued at $7,585,946. 5.30% of the stock is currently owned by company insiders.

Institutional Trading of Kestra Medical Technologies

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Corient Private Wealth LP boosted its stake in Kestra Medical Technologies by 284.2% during the second quarter. Corient Private Wealth LP now owns 60,614 shares of the company’s stock valued at $1,542,000 after buying an additional 44,839 shares in the last quarter. Sei Investments Co. raised its position in Kestra Medical Technologies by 22.6% in the first quarter. Sei Investments Co. now owns 237,116 shares of the company’s stock worth $4,726,000 after acquiring an additional 43,753 shares in the last quarter. Spartan Wealth Advisory Services LLC bought a new stake in Kestra Medical Technologies in the first quarter worth about $603,000. Bank of New York Mellon Corp lifted its holdings in Kestra Medical Technologies by 47.2% in the 1st quarter. Bank of New York Mellon Corp now owns 70,113 shares of the company’s stock valued at $1,397,000 after acquiring an additional 22,471 shares during the last quarter. Finally, Quantinno Capital Management LP acquired a new stake in Kestra Medical Technologies in the 1st quarter valued at about $431,000.

Kestra Medical Technologies Company Profile

Kestra Medical Technologies is a medical technology company focused on wearable solutions for people at risk of sudden cardiac arrest. Its products combine cardiac monitoring, treatment technology and digital services intended to support patients and their care teams. The company’s flagship product, the ASSURE wearable cardioverter defibrillator, continuously monitors a patient’s heart rhythm and can deliver a treatment shock if it detects a life-threatening arrhythmia. The system also provides alerts and supports remote sharing of patient data with clinicians.